New products in UPM Raflatac's extended portfolio include the latest high-performance solutions for primary blood bag labeling and a unique material for labeling sterilization wraps for surgical instruments in hospitals. And the addition of a destructible, non-reusable label face adds a second layer of security to an anti-counterfeiting range for compliance with the Falsified Medicines Directive.
Following an extensive, standards-compliant product development process, UPM Raflatac has produced a primary blood bag label stock range based on a unique adhesive - RP32 PB. Developed and tested according to guidance from the ISO 3826 standard, RP32 PB has high heat resistance and tolerates long-term storage in low-temperature environments. When paired with a selection of non-PVC label faces, this range is applicable for different market preferences.
UPM Raflatac has also launched a range of pharmaceutical labeling materials that support compliance with the Falsified Medicines Directive (2011/62/EU) regarding packaging for prescription drugs and high-risk, over-the-counter medicines.
By incorporating tamper-evident features as described in the new EN 16679, these products help protect the supply chain from counterfeit materials. RP62 EU adhesive produces cardboard tear on tampered pharmaceutical product packs, and clear film labels make these solutions compatible with existing packaging designs. A new destructible film label, Pharmaclear PP Seal, adds a second layer of security by preventing re-use of the label.
Other innovations include a unique material based on RP3H adhesive for labeling sterilization wraps for autoclaved surgical instruments; and unlike typical solutions, no additional tape is required to secure label adhesion. UPM Raflatac also supplies a wide range of solutions for labeling small-diameter containers from 15 mm to 7 mm.
